- XORTX Therapeutics has announced the receipt of notification that the patent “Formulations of Xanthine Oxidase Inhibitors” will be granted by the United States Patent Office (USPTO)
- The patent covers compositions for, and methods of using XORTX’s proprietary formulations of xanthine oxidase inhibitors for kidney and other diseases
- The 20-year protection afforded by this patent will cover XORTX’s first-in-class ADPKD therapy to address unmet medical needs in the US
- At present, there are few therapeutic options available to treat progressing kidney disease due to ADPKD or diabetic nephropathy
- XORTX is a pharmaceutical therapeutics company with two clinically advanced products in development
- XORTX Therapeutics Inc. was trading at $2.45 with a rise of $0.05 or 2.083 per cent at 2:16 PM ET
XORTX Therapeutics (XRTX) has received notification that the patent “Formulations of Xanthine Oxidase Inhibitors” will be granted by the USPTO.
The patent covers compositions for and methods of using XORTX’s proprietary formulations of xanthine oxidase inhibitors for renal and other diseases where aberrant purine metabolism has been implicated in disease progression.
XORTX’s XRx-008, for ADPKD program for autosomal dominant polycystic kidney disease (ADPKD), centres on a proprietary combination of uric acid lowering agents and other excipients.
At present, there are few therapeutic options available to treat progressing kidney disease due to ADPKD or diabetic nephropathy (DN).
The 20-year protection afforded by this patent will cover XORTX’s first-in-class ADPKD therapy to address unmet medical needs in the US. market size estimates for ADPKD for the United States, Europe, and globally are estimated at 150,000, 160,000, and 3,000,000, respectively.
ADPKD is a rare disease with orphan disease programs in the EU, the US and Japan protecting market exclusivity for 10, 7 and 10-year periods, respectively. Claims granted with this notice are specific to the composition of novel formulations of oxypurinol.
“This newly granted patent covers compositions of formulations key to XORTX’s platform technology and this issuance strengthens our intellectual property portfolio in the United States,” said Dr. Allen Davidoff, CEO of XORTX.
Polycystic kidney disease (PKD) is considered a rare disease with two main types – ADPKD and autosomal recessive PDK (“ARPKD”), with a prevalence of 1:800 and 1:20,000, respectively.
XORTX Therapeutics Inc. is a pharmaceutical therapeutics company with two clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus/COVID-19 infection, and XRx-221 is a clinical-stage program for Type 2 Diabetic Nephropathy (T2DN).
XORTX Therapeutics was trading at $2.45 with a rise of 2.083 per cent at 2:16 PM ET.
